Danielle Duffy
Overview
Explore the profile of Danielle Duffy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kingwell B, Nicholls S, Velkoska E, Didichenko S, Duffy D, Korjian S, et al.
J Am Heart Assoc
. 2022 Apr;
11(8):e024754.
PMID: 35411789
Approximately 12% of patients with acute myocardial infarction (AMI) experience a recurrent major adverse cardiovascular event within 1 year of their primary event, with most occurring within the first 90 ...
12.
Lee J, Chi G, Fitzgerald C, Kazmi S, Kalayci A, Korjian S, et al.
Front Cardiovasc Med
. 2021 Dec;
8:774418.
PMID: 34966797
Serum high-density lipoprotein cholesterol (HDL-C) levels are inversely associated with cardiovascular disease events. Yet, emerging evidence suggests that it is the functional properties of HDL, in particular, reverse cholesterol transport,...
13.
Zheng B, Duffy D, Tricoci P, Kastrissios H, Pfister M, Wright S, et al.
Br J Clin Pharmacol
. 2020 Nov;
87(6):2558-2571.
PMID: 33217027
Aims: To characterize relationships between apolipoprotein A-I (apoA-I) exposure and cholesterol efflux capacity (CEC) and covariate effects following CSL112 (apoA-I [human]) administration in an integrated population including acute myocardial infarction...
14.
Gibson C, Kastelein J, Phillips A, Aylward P, Yee M, Tendera M, et al.
Am Heart J
. 2020 Oct;
231:121-127.
PMID: 33065120
Acute myocardial infarction (MI) patients remain at high risk for recurrent events. Cholesterol efflux, mediated by apolipoprotein A-I, removes excess cholesterol from atherosclerotic plaque and transports it to the liver...
15.
Gibson C, Kerneis M, Yee M, Daaboul Y, Korjian S, Poyan Mehr A, et al.
Am Heart J
. 2018 Dec;
208:81-90.
PMID: 30580130
Background: CSL112 (apolipoprotein A-I [human]) is a plasma-derived apolipoprotein A-I developed for early reduction of cardiovascular risk following an acute myocardial infarction (AMI). The safety of CSL112 among AMI subjects...
16.
Gille A, Duffy D, Tortorici M, Wright S, Deckelbaum L, DAndrea D
J Clin Pharmacol
. 2018 Nov;
59(3):427-436.
PMID: 30452776
CSL112 (apolipoprotein A-I [human]) is a novel intravenous formulation of plasma-derived apolipoprotein A-I (apoA-I) that enhances cholesterol efflux capacity. Renal impairment is a common comorbidity in acute myocardial infarction patients...
17.
Tortorici M, Duffy D, Evans R, Feaster J, Gille A, Mant T, et al.
Clin Pharmacol Drug Dev
. 2018 Sep;
8(5):628-636.
PMID: 30240132
CSL112 (Apolipoprotein A-I [human]) is an intravenous preparation of apolipoprotein A-I (apoA-I), formulated with phosphatidylcholine (PC) and stabilized with sucrose, in development to prevent early recurrent cardiovascular events following acute...
18.
Dunbar R, Movva R, Bloedon L, Duffy D, Norris R, Navab M, et al.
Clin Transl Sci
. 2017 Aug;
10(6):455-469.
PMID: 28795506
A single dose of the apolipoprotein (apo)A-I mimetic peptide D-4F rendered high-density lipoprotein (HDL) less inflammatory, motivating the first multiple-dose study. We aimed to assess safety/tolerability, pharmacokinetics, and pharmacodynamics of...
19.
Valentino M, Danaf J, Panakos A, Ragupathi L, Duffy D, Whellan D
Am Heart J
. 2016 Nov;
181:130-136.
PMID: 27823684
Background: The 2013 American College of Cardiology/American Heart Association cholesterol management guidelines represented a paradigm shift from the National Cholesterol Education Program Adult Treatment Panel III guidelines, replacing low-density lipoprotein...
20.
Ahmad Z, Andersen R, Andersen L, OBrien E, Kindt I, Shrader P, et al.
J Clin Lipidol
. 2016 Sep;
10(5):1223-9.
PMID: 27678440
Background: In the US familial hypercholesterolemia (FH), patients are underidentified, despite an estimated prevalence of 1:200 to 1:500. Criteria to identify FH patients include Simon Broome, Dutch Lipid Clinic Network...